EN DE
Watch Helius Medical Technologies Inc Class A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Helius Medical Technologies Inc Class A (HSDT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Helius Medical Technologies Inc Class A stock $3.28, price $1.93, upside +70.0%, quality 27 out of 100. Rating: strongly undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Financial Services US

HM Helius Medical Technologies Inc Class A logo Thin data Nov 8, 2026

Helius Medical Technologies Inc Class A

HSDT · US
Cheap, value-trap risk

The stock costs 41% less than our calculation considers fair.

Fair value $3.28 · Strongly undervalued
Costs just 0 times its yearly profit.
Mixed Growth (revenue 5y +55.5 %/yr in USD)
Mixed vs. peers (4/8)
Quality 27/100
Negative free cash flow
Narrow moat 5/100
Thin data
⚠ Dilution
Watch Helius Medical Technologies Inc Class A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$590,250 $1.27 Fair Value $3.28 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $1.27 – $590,250 · fair‑value band $2.47 – $4.10 · the $1.93 price screens below the $3.28 fair value. As of Nov 8, 2026.

Follow Helius Medical Technologies Inc Class A in your weekly email

Every Wednesday you see whether Helius Medical Technologies Inc Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications. It also focuses on neurological wellness.

Show moreShow less

In addition, the company offers Portable Neuromodulation Stimulator, a non-implantable medical device, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. Solana Company is headquartered in Newtown, Pennsylvania.

Stock analysis

Helius Medical Technologies Inc Class A (HSDT) currently trades at $1.93, while our model-based Fair Value estimate is $3.28, implying the stock looks roughly 41% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $2.47 (bear) to $4.10 (bull), the price of $1.93 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Financial Services sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Helius Medical Technologies Inc Class A reported revenue of $6.0M in FY2025 versus $522K in FY2021, a compound +84.3%/yr. Reported net income was −$40.9M in FY2025.

Key figures

Market cap $151M Micro · P/E ratio 0.0 · P/S ratio 12.0 · EPS (TTM) $53.74 · Return on equity −179% · Return on assets (EBIT) −156% (5-year average) · Operating margin −1,293% · Revenue (TTM) $12.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and 52% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −16% fair-value upside, at 70%, HSDT screens cheaper than that median.

Fair Value models

Bear $2.47 Fair Value $3.28 Bull $4.10
Price $1.93 · Upside +70.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($46.08 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
P/B Multiple $2.95 $3.93 $4.91 55
NCAV (Graham) $0.2900 $0.4300 $0.5400 52
All 2 models by family
Multiples
P/B Multiple $2.95 $3.93 $4.91 55
Asset-Based
NCAV (Graham) $0.2900 $0.4300 $0.5400 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,057.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+97.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.5%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,129.5% (2020) → −351.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch HSDT, get fair value alerts →

Compare Helius Medical Technologies Inc Class A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 587 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +70.0% · Above median
Profitability
Return on assets −13.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 57.7% · Top 25%

Valuation Multiplesvs Asset Management median · lower = cheaper

P/E (12 months) 0.0× · Cheapest 25%
P/B 0.50× · Cheapest 25%
P/S (12 months) 12.51× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 60
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 80

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Exor N.V EXO €73.35 €139.37 +90% vs HSDT
Raymond James Financial, Inc RJF $162.81 $281.42 +73% vs HSDT
Apollo Global Management, Inc APO $116.75 $197.52 +69% vs HSDT
Ameriprise Financial, Inc AMP $501.49 $609.56 +22% vs HSDT
State Street Corporation STT $165.56 $139.37 −16% vs HSDT
Ares Management Corporation ARES $133.98 $99.35 −26% vs HSDT
Northern Trust Corporation NTRS $172.76 $123.42 −29% vs HSDT
Brookfield Asset Management Ltd BAM $52.95 $31.26 −41% vs HSDT
Blackstone Inc BX $119.50 $52.29 −56% vs HSDT
KKR & Co KKR $96.48 $27.32 −72% vs HSDT

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Helius Medical Technologies Inc Class A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Helius Medical Technologies Inc Class A Fair Value". https://www.fairvalue-calculator.com/stock/HSDT

Frequently asked questions

Is Helius Medical Technologies Inc Class A (HSDT) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $3.28 versus a price of $1.93, about +70% upside (undervalued).
What is the fair value of HSDT?
Our model-based fair value for Helius Medical Technologies Inc Class A is $3.28 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.93.
What is the quality score of HSDT?
Helius Medical Technologies Inc Class A has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Helius Medical Technologies Inc Class A (HSDT)?
Our model-based price target is the fair value of $3.28 (as of Nov 8, 2026) from 2 valuation models. Cautious scenario $2.47, optimistic scenario $4.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Helius Medical Technologies Inc Class A stock forecast for 2026?
Our models put fair value at $3.28, about +70% upside versus a price of $1.93 (undervalued). Cautious scenario $2.47, optimistic scenario $4.10. The calculation is refreshed regularly with new filings.
What is the revenue of Helius Medical Technologies Inc Class A (HSDT)?
Helius Medical Technologies Inc Class A reported trailing-twelve-month revenue of about $12.1M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Helius Medical Technologies Inc Class A (HSDT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Helius Medical Technologies Inc Class A it is $3.28 per share (as of Nov 8, 2026), against a price of $1.93. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Helius Medical Technologies Inc Class A stock overvalued or undervalued in 2026?
As of Nov 8, 2026, HSDT trades below its calculated fair value: price $1.93, fair value $3.28, a gap of about +70% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HSDT?
No. The price is what the market pays today ($1.93); the fair value is what the company's own numbers justify ($3.28). For Helius Medical Technologies Inc Class A the two are $1.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Helius Medical Technologies Inc Class A worth?
The market values Helius Medical Technologies Inc Class A at about $151M (market capitalisation, as of Nov 8, 2026). Per share that is $1.93; our models calculate a fair value of $3.28 per share.
What do the bullish and bearish scenarios say about HSDT?
Our models span a range for Helius Medical Technologies Inc Class A: cautious scenario $2.47, base $3.28, optimistic $4.10 per share (as of Nov 8, 2026, price $1.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HSDT?
Helius Medical Technologies Inc Class A trades at a price-to-earnings ratio of 0.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.28 is built from several models across several years. Other multiples: P/B 0.5, P/S 12.5.
How solid is the balance sheet of Helius Medical Technologies Inc Class A (HSDT)?
Balance-sheet figures for Helius Medical Technologies Inc Class A (as of Nov 8, 2026): return on equity −179.0%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is HSDT from its 52-week high?
Helius Medical Technologies Inc Class A trades at $1.93, about 65% below its 52-week high of $5.50 and 52% above the low of $1.27 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.28 is for.
Which stocks are comparable to Helius Medical Technologies Inc Class A?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Asset Management Ltd, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Helius Medical Technologies Inc Class A stock attractive at the current price?
The data as of Nov 8, 2026: price $1.93, calculated fair value $3.28 (+70%), Quality Score 27/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HSDT calculated?
We run Helius Medical Technologies Inc Class A through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of $3.28 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Helius Medical Technologies Inc Class A currently trades 41% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Helius Medical Technologies Inc Class A (HSDT)?
The closing price on Nov 6, 2026 was $1.93. Our model-based fair value is $3.28, about +70% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Helius Medical Technologies Inc Class A right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($2.47). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Helius Medical Technologies Inc Class A

How large is the market capitalisation of Helius Medical Technologies Inc Class A (HSDT)?
The market capitalisation of Helius Medical Technologies Inc Class A is $151M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Helius Medical Technologies Inc Class A (HSDT)?
The price-to-sales ratio of Helius Medical Technologies Inc Class A is 12.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Helius Medical Technologies Inc Class A (HSDT)?
Earnings per share at Helius Medical Technologies Inc Class A are $53.74 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Helius Medical Technologies Inc Class A (HSDT)?
The return on equity (ROE) of Helius Medical Technologies Inc Class A is −179% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Helius Medical Technologies Inc Class A (HSDT)?
On an EBIT basis the return on assets of Helius Medical Technologies Inc Class A is −156% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Helius Medical Technologies Inc Class A (HSDT)?
The operating margin of Helius Medical Technologies Inc Class A is −1,293% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Helius Medical Technologies Inc Class A (HSDT)?
Revenue at Helius Medical Technologies Inc Class A is growing +57.7% versus a year earlier (3y avg +97.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Helius Medical Technologies Inc Class A (HSDT) generate?
The free cash flow of Helius Medical Technologies Inc Class A is −$61.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Helius Medical Technologies Inc Class A (HSDT) hold?
Helius Medical Technologies Inc Class A holds more cash than debt, $7.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Helius Medical Technologies Inc Class A in the live analysis

One click puts Helius Medical Technologies Inc Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.